Home » Newsletters » BioWorld Science

BioWorld Science

March 28, 2019

View Archived Issues

Human TRIM5-alpha active against HIV

Immunogenicity aids chemotherapy as well

sEH activity is involved in offspring neurodevelopmental disorders after maternal immune activation

Identification of imidazopyrazine-derived TAK1 inhibitors with in vitro and in vivo efficacy

Dual inhibitor of CKI-alpha and -delta can help to control circadian rhythms

Inhibition of RIP1 kinase arrests demyelination progression at the stage of monocyte activation

Novel quinolylnitrone with antioxidant neuroprotective effect for ischemic stroke

Targeting intracellular PD-L1 strengthens checkpoint blockade

Probiotics for treating autism prepared at Beijing Jinfeng Labs Technology

Daiichi Sankyo initiates dosing in phase III AMELA study of mirogabalin

Kalyra Pharmaceuticals starts phase I study of KP-1199

Urovant Sciences launches international phase III COURAGE study of vibegron

Positive phase I/II mid-study results reported for ApoGraft

Bristol-Myers Squibb discovers STING agonists

New monoglyceride lipase inhibitors described by Abide Therapeutics

Angion Biomedica identifies Rho-associated protein kinase 1/2 inhibitors

Dana-Farber Cancer Institute presents new EGFR and/or HER2 inhibitors

New first-in-human study to explore use of ODM-209 in advanced prostate and breast cancers

Biohaven begins phase II study of BHV-3500 for acute treatment of migraine

Promising topline results from pivotal phase II study of enfortumab vedotin in urothelial cancer

C-peptide predicts diazoxide efficacy in neonates with hyperinsulinism hypoglycemia

Cancer Research UK, LifeArc and Ono establish immuno-oncology drug discovery alliance

S100A4 identified as a marker of polycystic ovary syndrome and treatment response

Tricida reports results from extension trial of TRC-101 in CKD patients with metabolic acidosis

Madrigal initiates phase III trial of MGL-3196 in NASH

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 11, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...